1-3 of 3
Danielle van Lammeren-Venema
Close
Sort by
Journal Articles

Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial

Clinical Trials & Observations
Anita W. Rijneveld, Bronno van der Holt, Okke de Weerdt, Bart J. Biemond, Arjen A. van de Loosdrecht, Lotte E. van der Wagen, Mar Bellido, Michel van Gelder, Walter J. F. M. van der Velden, Dominik Selleslag, Daniëlle van Lammeren-Venema, Constantijn J. M. Halkes, Rob Fijnheer, Violaine Havelange, Geerte L. van Sluis, Marie-Cecile Legdeur, Dries Deeren, Alain Gadisseur, Harm A. M. Sinnige, Dimitri A. Breems, Aurélie Jaspers, Ollivier Legrand, Wim E. Terpstra, Rinske S. Boersma, Dominiek Mazure, Agnes Triffet, Lidwine W. Tick, Karolien Beel, Johan A. Maertens, H. Berna Beverloo, Marleen Bakkus, Christa H. E. Homburg, Valerie de Haas, Vincent H. J. van der Velden, Jan J. Cornelissen, the Dutch-Belgian HOVON Cooperative group
Journal: Blood Advances
Blood Adv (2022) 6 (4): 1115–1125.
https://doi.org/10.1182/bloodadvances.2021005624
Published: 2022
Includes: Supplemental data
Journal Articles

Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Clinical Trials & Observations
Bob Löwenberg, Thomas Pabst, Johan Maertens, Patrycja Gradowska, Bart J. Biemond, Olivier Spertini, Edo Vellenga, Laimonas Griskevicius, Lidwine W. Tick, Mojca Jongen-Lavrencic, Marinus van Marwijk Kooy, Marie-Christiane Vekemans, Walter J. F. M. van der Velden, Berna Beverloo, Lucienne Michaux, Carlos Graux, Dries Deeren, Okke de Weerdt, Joost W. J. van Esser, Mario Bargetzi, Saskia K. Klein, Alain Gadisseur, Peter E. Westerweel, Hendrik Veelken, Michael Gregor, Tobias Silzle, Daniëlle van Lammeren-Venema, Ine Moors, Dimitri A. Breems, Mels Hoogendoorn, Marie-Cecile J. C. Legdeur, Thomas Fischer, Juergen Kuball, Jan Cornelissen, Kimmo Porkka, Gunnar Juliusson, Peter Meyer, Martin Höglund, Bjorn T. Gjertsen, Jeroen J. W. M. Janssen, Gerwin Huls, Jakob Passweg, Jacqueline Cloos, Peter J. M. Valk, Catharina H. M. J. van Elssen, Markus G. Manz, Yngvar Floisand, Gert J. Ossenkoppele
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1110–1121.
https://doi.org/10.1182/bloodadvances.2020003855
Published: 2021
Includes: Supplemental data
Journal Articles

Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS

Clinical Trials & Observations
Gerwin Huls, Dana A. Chitu, Thomas Pabst, Saskia K. Klein, Georg Stussi, Laimonas Griskevicius, Peter J. M. Valk, Jacqueline Cloos, Arjan A. van de Loosdrecht, Dimitri Breems, Danielle van Lammeren-Venema, Isabelle van Zeventer, Rinske Boersma, Mojca Jongen-Lavrencic, Martin Fehr, Mels Hoogendoorn, Markus G. Manz, Maaike Söhne, Rien van Marwijk Kooy, Dries Deeren, Marjolein W. M. van der Poel, Marie Cecile Legdeur, Lidwine Tick, Yves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg, Gert J. Ossenkoppele
Journal: Blood Advances
Blood Adv (2020) 4 (18): 4267–4277.
https://doi.org/10.1182/bloodadvances.2020002846
Published: 2020
Includes: Supplemental data